MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Alaunos Therapeutics, Inc. (NASDAQ: TCRT), formerly, Ziopharm
Organization & Developments: Alaunos
Parents
Alaunos Therapeutics, Inc. (NASDAQ: TCRT), formerly, Ziopharm
Children
2022: Alaunos Therapeutics Still Waiting For Home Run_ seekingalpha.com
2022: Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data_seekingalpha.com
2022: Alaunos: Taking Autologous T-Cell Receptor Therapies To The Next Step_seekingalpha.com
Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy.
T-cell receptor ("TCR") T-cell therapies
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
Jumps
Finance & Acquisitions: Alaunos
Key People: Alaunos